ArticleBlood2010
The multifaceted granulysin.
Article in Blood, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 16 citations in OpenAlex.
- Article
- Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN): could retinoids play a causative role?Medical science monitor : international medical journal of experimental and clinical research · 2015Review
- The dendritic cell response to classic, emerging, and homeostatic danger signals. Implications for autoimmunity.Frontiers in immunology · 2013Article
- Cell death mechanisms at the maternal-fetal interface: insights into the role of granulysin.Clinical & developmental immunology · 2012Review
- 15 kDa Granulysin versus GM-CSF for monocytes differentiation: analogies and differences at the transcriptome level.Journal of translational medicine · 2011Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Granulysin is a cytolytic and proinflammatory peptide contained in the cytotoxic granules of NK cells and CTL. Unexpectedly, granulysin also recruits and activates dendritic cells via TLR4/Myd88, playing the role of an immune adjuvant. Hence, in contrast to classical alarmins released by early leukocytes, granulysin is the first alarmin to be released from lymphocytes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.